Roche Holding Ltd. (VTX:ROG) has been given a CHF 260 price objective by equities research analysts at Morgan Stanley in a research note issued to investors on Friday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. Morgan Stanley’s target price would indicate a potential upside of 12.99% from the stock’s current price.
A number of other brokerages have also recently commented on ROG. Deutsche Bank AG set a CHF 254 price target on Roche Holding and gave the company a “neutral” rating in a research note on Friday. Jefferies Group LLC set a CHF 290 price target on Roche Holding and gave the company a “buy” rating in a research note on Thursday. J P Morgan Chase & Co reiterated a “buy” rating on shares of Roche Holding in a research note on Friday. Credit Suisse Group set a CHF 300 price target on Roche Holding and gave the company a “buy” rating in a research note on Monday, September 11th. Finally, The Goldman Sachs Group, Inc. set a CHF 325 price target on Roche Holding and gave the company a “buy” rating in a research note on Monday, September 11th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of CHF 262.69.
Shares of Roche Holding (ROG) traded up CHF 1.10 on Friday, hitting CHF 230.10. The stock had a trading volume of 2,370,000 shares, compared to its average volume of 1,630,000. Roche Holding has a one year low of CHF 218.30 and a one year high of CHF 273.
ILLEGAL ACTIVITY NOTICE: “Roche Holding Ltd. (ROG) Given a CHF 260 Price Target by Morgan Stanley Analysts” was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another website, it was illegally stolen and republished in violation of US & international trademark & copyright laws. The legal version of this news story can be accessed at https://ledgergazette.com/2017/11/17/roche-holding-ltd-rog-given-a-chf-260-price-target-by-morgan-stanley-analysts.html.
About Roche Holding
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Holding Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holding Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.